7.1
Neuromuscular Junction And Blockade
The site of chemical communication between a motor neuron and a muscle fiber is called the neuromuscular junction (NMJ). The end of the motor neuron a…
The neuromuscular junction, or NMJ, is a site of chemical communication between a motor neuron and muscle fiber to facilitate skeletal muscle contraction. Drugs called neuromuscular blockers target the NMJ and help induce muscle paralysis.
The NMJ consists of the motor nerve terminal and a muscle fiber's motor end plate separated by a small synaptic cleft. Acetylcholine, a neurotransmitter released from the nerve terminal, acts as a chemical messenger between the two cells.
When an action potential reaches the neuronal end, it triggers the release of acetylcholine into the synaptic cleft. Acetylcholine binds to the nicotinic receptors on the motor endplate and opens ion channels to allow sodium ions into the cell.
The influx of sodium ions depolarizes the muscle membrane, propagating the action potential and causing muscle contraction.
Because of their structural similarity with acetylcholine, neuromuscular blockers can bind to the nicotinic receptors and block impulse transmission.
For example, succinylcholine competes with acetylcholine to bind the receptors and inhibit its action. Such neuromuscular blockade makes the muscles relax in sedated patients during surgery.
View the full transcript and gain access to JoVE Core videos
Q1: What is the neuromuscular junction and what role does it play in muscle contraction?
The neuromuscular junction (NMJ) is a site of chemical communication between a motor neuron and muscle fiber that facilitates skeletal muscle contraction. It consists of the motor nerve terminal, synaptic cleft, and motor end plate. When an action potential reaches the nerve terminal, it triggers acetylcholine release into the synaptic cleft, enabling impulse transmission across the NMJ and initiating muscle contraction.
Q2: How does acetylcholine trigger muscle contraction at the neuromuscular junction?
Acetylcholine, released from synaptic vesicles, binds to nicotinic receptors on the motor end plate. Two acetylcholine molecules open sodium ion channels, allowing Na+ influx that depolarizes the muscle membrane. This depolarization propagates an action potential along the muscle fiber, triggering muscle contraction. Acetylcholinesterase then breaks down acetylcholine to terminate the signal.
Q3: What is the mechanism by which neuromuscular blockers induce muscle paralysis?
Neuromuscular blockers bind to nicotinic receptors on the motor end plate, blocking acetylcholine from attaching and preventing impulse transmission across the NMJ. Because of their structural similarity with acetylcholine, drugs like succinylcholine compete for receptor binding sites. This blockade prevents sodium influx and action potential propagation, resulting in muscle relaxation and temporary paralysis during surgery.
Q4: How do botulinum toxin and tubocurarine differ in blocking neuromuscular transmission?
Botulinum toxin prevents acetylcholine release by blocking exocytosis of synaptic vesicles at the nerve terminal. Tubocurarine and similar nondepolarizing blockers bind to acetylcholine receptors on the motor end plate, preventing acetylcholine attachment. Both agents block impulse transmission but act at different sites within the NMJ to prevent muscle contraction.
Q5: What role does calcium play in acetylcholine release at the neuromuscular junction?
When a nerve impulse arrives at the synaptic bulb, it opens calcium channels, allowing Ca2+ influx into the nerve terminal. This calcium influx stimulates exocytosis of synaptic vesicles, releasing acetylcholine into the synaptic cleft. Without calcium entry, acetylcholine cannot be released, preventing neuromuscular transmission and muscle contraction.
Q6: Why are neuromuscular blockers used during surgical procedures?
Neuromuscular blockers induce muscle relaxation and temporary paralysis by blocking impulse transmission at the NMJ, making them valuable during surgery. They prevent involuntary muscle movement, allowing surgeons better access and control during procedures. This pharmacological paralysis is reversible and essential for anesthesia management in operating rooms.
Q7: What structural features allow neuromuscular blockers to interfere with acetylcholine function?
Neuromuscular blockers possess structural similarity to acetylcholine, enabling them to bind to nicotinic receptors on the motor end plate. This structural mimicry allows them to compete with acetylcholine for receptor binding sites. By occupying these receptors, blockers prevent acetylcholine attachment and subsequent ion channel opening, effectively halting neuromuscular transmission.